StockData

Vanda Pharmaceuticals Inc. (VNDA) stock

VNDANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3055% below fair value
$3.75−0.06 (-1.57%)

Close on Nov 18, 2026Market cap $226.76MP/E –Yield –

Vanda Pharmaceuticals total assets

Total assets on the balance sheet at the end of each period.

Vanda Pharmaceuticals's total assets was $382.33M at Sep 30, 2026. For fiscal 2025 it was $488.95M, down 25.5% from the year before. Over ten years it grew 8.7% a year on average. The highest annual figure on record is $656.20M in fiscal 2024.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$488.95M-25.5%
FY2024Dec 31, 2024$656.20M+1.2%
FY2023Dec 31, 2023$648.44M+2.2%
FY2022Dec 31, 2022$634.25M+6.8%
FY2021Dec 31, 2021$593.79M+11.3%
FY2020Dec 31, 2020$533.46M+10.3%
FY2019Dec 31, 2019$483.75M+45.7%
FY2018Dec 31, 2018$332.13M+61.7%
FY2017Dec 31, 2017$205.43M-2.4%
FY2016Dec 31, 2016$210.37M-1.3%
FY2015Dec 31, 2015$213.05M+24.1%
FY2014Dec 31, 2014$171.70M+19.8%
FY2013Dec 31, 2013$143.35M+5.8%
FY2012Dec 31, 2012$135.45M-25.8%
FY2011Dec 31, 2011$182.62M-14.3%
FY2010Dec 31, 2010$213.10M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$382.33M-36.4%
Q2 FY2026Jun 30, 2026$412.47M-34.0%
Q1 FY2026Mar 31, 2026$433.53M-31.4%
Q4 FY2025Dec 31, 2025$488.95M-25.5%
Q3 FY2025Sep 30, 2025$601.14M-6.8%
Q2 FY2025Jun 30, 2025$624.75M-4.1%
Q1 FY2025Mar 31, 2025$631.94M-3.2%
Q4 FY2024Dec 31, 2024$656.20M+1.2%
Q3 FY2024Sep 30, 2024$645.12M+0.5%
Q2 FY2024Jun 30, 2024$651.37M+1.5%
Q1 FY2024Mar 31, 2024$652.68M+1.3%
Q4 FY2023Dec 31, 2023$648.44M+2.2%
Q3 FY2023Sep 30, 2023$641.61M+3.2%
Q2 FY2023Jun 30, 2023$641.68M+5.3%
Q1 FY2023Mar 31, 2023$644.53M+6.8%
Q4 FY2022Dec 31, 2022$634.25M+6.8%
Q3 FY2022Sep 30, 2022$621.79M+7.2%
Q2 FY2022Jun 30, 2022$609.10M+7.3%
Q1 FY2022Mar 31, 2022$603.56M+11.1%
Q4 FY2021Dec 31, 2021$593.79M+11.3%
Q3 FY2021Sep 30, 2021$579.77M+12.4%
Q2 FY2021Jun 30, 2021$567.65M+12.0%
Q1 FY2021Mar 31, 2021$543.19M+11.2%
Q4 FY2020Dec 31, 2020$533.46M+10.3%
Q3 FY2020Sep 30, 2020$515.91M+8.7%
Q2 FY2020Jun 30, 2020$506.63M+36.0%
Q1 FY2020Mar 31, 2020$488.53M+39.1%
Q4 FY2019Dec 31, 2019$483.75M+45.7%
Q3 FY2019Sep 30, 2019$474.45M+52.1%
Q2 FY2019Jun 30, 2019$372.48M+23.0%
Q1 FY2019Mar 31, 2019$351.17M+10.7%
Q4 FY2018Dec 31, 2018$332.13M+61.7%
Q3 FY2018Sep 30, 2018$311.94M+51.6%
Q2 FY2018Jun 30, 2018$302.93M+43.8%
Q1 FY2018Mar 31, 2018$317.32M+55.0%
Q4 FY2017Dec 31, 2017$205.43M-2.4%
Q3 FY2017Sep 30, 2017$205.71M–
Q2 FY2017Jun 30, 2017$210.67M–
Q1 FY2017Mar 31, 2017$204.72M–
Q4 FY2016Dec 31, 2016$210.37M–

More Vanda Pharmaceuticals figures

See a number that looks wrong?